• This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Sun - Fri 8:00 - 20:30
CollPlant

CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, announced that its ordinary shares have been approved for trading on the Nasdaq.

Global Market®  under the Company's current ticker symbol "CLGN" and will begin trading at the open of market on June 4, 2021. At such time, the Company's American Depositary Shares (ADSs) will be mandatorily cancelled and exchanged for ordinary shares at a one-for-one ratio. Shareholders holding their ADSs in book-entry or through a bank, broker or other nominee form do not need to take any action in connection with the mandatory exchange.

"Meeting the requirements for the Nasdaq Global Market® demonstrates CollPlant's growth, financial performance and stability," said Yehiel Tal, CollPlant CEO. "The listing of our ordinary shares on the Nasdaq Global Market® and transition to trading of ordinary shares is designed to elevate our visibility within the institutional marketplace, eliminate ADS commission depositary fees for our shareholders, and enhance our ability to broaden our shareholder base with the goal of driving long-term shareholder value."

A listing on the Nasdaq Global Market® is considered an indicator of status and success for companies that qualify for listing. Listed companies must satisfy stringent financial, liquidity and corporate governance requirements, both initially and on an ongoing basis.

For more information, visit http://www.collplant.com.

Company Name: CollPlant
About Company: CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine. CollPlant recently entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.
Person of Contact: Eran Rotem
Designation: Deputy CEO & Chief Financial Officer